EyePoint (STU:PV3B) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PV3B EyePoint Inc STU:PV3B
41 GF Score
Price €11.30
GF Value €0.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is EyePoint FFO?

FFO (Funds from operations) only applies to REITs.

STU:PV3B
41GF Score
EyePoint Inc STU:PV3B
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is EyePoint (STU:PV3B) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of €11.30 is trading 1612.1% above its estimated GF Value™ of €0.66. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for STU:PV3B:

  • FFO:
  • GF Value™: €0.66 vs. price of €11.30 (1612.1% above fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the STU:PV3B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


EyePoint Business Description

Other Exchanges EYPT:USA
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
41GF Score

Get the complete analysis for STU:PV3B

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.30
Price
€0.66
GF Value